Novel drug delivery method for DR patients

Novel drug delivery method for DR patients

PREVIN combines a novel drug delivery method to treat patients with Diabetic Retinopathy (DR) (i.e. blindness in Diabetes patients) with established drugs.

This method will improve localized drug delivery with cyclodextrin nanoparticles to the back of the eye for effective, safe, low-cost, preventive and non-invasive treatment of Diabetic Retinopathy. PREVIN, supported by extensive safety and efficacy studies, will be ready for licensing within one year after the end of the project.Participants in the project are the Medical University Of ViennaOculis PharmaExperimentica LtdUniversity Of Copenhagen, Zealand University Hospital and Nucro-technics, A Division Of The Vimy Ridge Group Ltd.

The project was awarded a Eurostars grant.

All services

In our approach we combine both non-dilutive and dilutive funding. Let’s start working on your project together now!


Welcome at Catalyze!

Catalyze uses cookies in order to improve your user experience. By using this website you agree to our policy.

Go back or